ATAI Life Sciences NV ATAI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ATAI is a good fit for your portfolio.
News
-
Thinking about buying stock in Akebia Therapeutics, Mind Medicine, ATAI Life Sciences, Doma Holdings, or Iterum Therapeutics?
-
Thinking about buying stock in Lexicon Pharmaceuticals, Cassava Sciences, Clearside Biomedical, Lantern Pharma, or ATAI Life Sciences?
-
FDA issues guidance on psychedelic drug clinical trials
Trading Information
- Previous Close Price
- $1.87
- Day Range
- $1.87–2.07
- 52-Week Range
- $1.03–2.85
- Bid/Ask
- $1.97 / $2.00
- Market Cap
- $327.07 Mil
- Volume/Avg
- 1.2 Mil / 1.7 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 996.46
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 83
- Website
- https://www.atai.life
Comparables
Valuation
|
Metric
|
ATAI
|
PHVS
|
NAMS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.35 | 2.57 | 5.79 |
Price/Sales | 996.46 | — | 117.97 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ATAI
|
PHVS
|
NAMS
|
|---|---|---|---|
Quick Ratio | 9.02 | 9.85 | 6.86 |
Current Ratio | 9.22 | 10.46 | 6.95 |
Interest Coverage | −14.49 | — | — |
Quick Ratio
ATAI
PHVS
NAMS
Profitability
|
Metric
|
ATAI
|
PHVS
|
NAMS
|
|---|---|---|---|
Return on Assets (Normalized) | −28.57% | −50.56% | −34.73% |
Return on Equity (Normalized) | −33.78% | −56.14% | −39.45% |
Return on Invested Capital (Normalized) | −30.99% | −56.14% | −41.57% |
Return on Assets
ATAI
PHVS
NAMS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ndnbsffkm | Gmhp | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gwpsdpft | Mzlsft | $104.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Tlpdnmjfx | Xvlnk | $98.8 Bil | |
MRNA
| Moderna Inc | Rxgpjkl | Gwh | $38.8 Bil | |
ARGX
| argenx SE ADR | Fhxljnjjn | Jxhyv | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Pkthwxpd | Qwkq | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Tjgntpkr | Vcdmyy | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gxygyxynv | Sbjkchn | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lzvkwhptb | Xhwtj | $12.4 Bil | |
INCY
| Incyte Corp | Bhsbqzt | Vlqyfy | $11.9 Bil |